VivoSeq
Oncology

Oropharynx Squamous Cell Carcinoma

10

Pipeline Programs↗

1

Active Trials↗

10

Companies Involved↗

Oropharynx Squamous Cell Carcinoma is an early-stage landscape with 10 programs across 10 companies. The most active players are McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc., Merck & Co., Bristol-Myers Squibb. 3 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

37/100

Pipeline Velocity

0/100

Mech. Concentration

29/100

Completion Rate

0/100

Attrition Rate

33/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 2Merck & Co. logo

Merck & Co.

1 program

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 2AstraZeneca logo

AstraZeneca

1 program

Phase 2Regeneron logo

Regeneron

1 program

Phase 2Sanofi logo

Sanofi

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

10programs
Small molecule550%
Monoclonal antibody550%

Modality classified for 100% of 10 pipeline programs.

Analysis

Trial Status

3

clinical trials

Unknown status1 · 33%
Withdrawn1 · 33%
Active, not recruiting1 · 33%

Clinical Trials

Trial Activity

Cetuximab & Concomitant-Boost Accelerated RT in Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma.
Unknown status·TTrial Form Support S.L.·Phase 2·NCT00251381·90 enrolled
Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma
Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT05535023
Surgery Followed by Risk-Directed Post-Operative Adjuvant Therapy for HPV-Related Oropharynx Squamous Cell Carcinoma: "The Minimalist Trial (MINT)"
Active, not recruiting·WWashington University School of Medicine·Phase 2·NCT03621696·63 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)